{"id":4821,"date":"2023-03-30T17:45:10","date_gmt":"2023-03-30T15:45:10","guid":{"rendered":"https:\/\/amoeba-nature.com\/?p=4821"},"modified":"2023-03-30T17:56:40","modified_gmt":"2023-03-30T15:56:40","slug":"amoeba-2022-results","status":"publish","type":"post","link":"https:\/\/amoeba-nature.com\/en\/amoeba-2022-results\/","title":{"rendered":"Amo\u00e9ba : 2022 results\u00a0"},"content":{"rendered":"
\n

Amo\u00e9ba : 2022 annual results \u2013 An exceptional year which confirms Amo\u00e9ba\u2019s potential<\/h1>\n<\/div><\/div><\/div>\n\n
\n

Obtention of two marketing approvals in the USA (biocide and plant protection) and a recommendation for approval of the biocontrol active substance in Europe<\/strong><\/strong><\/h3>\n<\/div><\/div><\/div>\n\n
\n

Chassieu (France), March 30th<\/sup>, 2023 \u2013 17:45 \u2013 AMO\u00c9BA (FR0011051598 \u2013 ALMIB), <\/strong>an industrial biotech in pre-commercialization* specializing in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, today announces its annual results for the year ending 31 December 2022.<\/p>\n<\/div><\/div><\/div>\n\n

\n

The Board of Directors, which met on 30 March 2023, approved the corporate and consolidated financial statements of the Amoeba Group for the year ended 31 December 2022.<\/p>\n<\/div><\/div><\/div>\n\n

\n

The Statutory Auditors have carried out their audit work and have not identified any significant anomalies that would call into question the conformity of the financial statements. The certification reports are being issued<\/p>\n<\/div><\/div><\/div>\n\n\n

\"\"<\/figure>\n\n\n
\n

A financial position strongly improved by debt repayment and equity rebuilding<\/strong><\/h3>\n<\/div><\/div><\/div>\n\n
\n

At 31 December 2022, Amo\u00e9ba’s operating profit<\/strong> was -5,843 K\u20ac compared to -5,579 K\u20ac at 31 December 2021<\/p>\n<\/div><\/div><\/div>\n\n

\n